Cover for Adenosine Receptors and Parkinson's Disease

Adenosine Receptors and Parkinson's Disease

Book2000

Edited by:

Hiroshi Kase, Peter J. Richardson and Peter Jenner

Adenosine Receptors and Parkinson's Disease

Book2000

 

Cover for Adenosine Receptors and Parkinson's Disease

Edited by:

Hiroshi Kase, Peter J. Richardson and Peter Jenner

Browse this book

Book description

This book is the first definitive overview on adenosine receptor antagonists and their application to the treatment of Parkinson's Disease. The effect of these novel non-dopamine d ... read full description

Browse content

Table of contents

Actions for selected chapters

Select all / Deselect all

  1. Full text access
  2. Book chapterAbstract only

    Chapter 1 - Introductory Remarks: Adenosine A2A Receptor Antagonists: A Novel Approach to the Treatment of Parkinson's Disease

    Hiroshi Kase

    Pages 1-15

  3. Book chapterAbstract only

    Chapter 2 - Localization of Adenosine Receptors in Brain and Periphery

    Sarah J. Augood, Piers C. Emson and David G. Standaert

    Pages 17-30

  4. Book chapterAbstract only

    Chapter 3 - Medicinal Chemistry of Adenosine Receptors in Brain and Periphery

    Junichi Shimada and Fumio Suzuki

    Pages 31-48

  5. Book chapterAbstract only

    Chapter 4 - Overview of the Physiology and Pharmacology of Adenosine in the Peripheral System

    Akira Karasawa

    Pages 49-76

  6. Book chapterAbstract only

    Chapter 5 - Biochemical Characterization of Adenosine Agonists and Antagonists

    Hiromi Nonaka and Michio Ichimura

    Pages 77-i

  7. Book chapterAbstract only

    Chapter 6 - Physiology of Adenosine Receptors in the Striatum: Regulation of Striatal Projection Neurons

    Akihisa Mori and Tomomi Shindou

    Pages 107-127

  8. Book chapterAbstract only

    Chapter 7 - Regulation of Neurotransmitter Release in Basal Ganglia by Adenosine Receptor Agonists and Antagonists in Vitro and in Vivo

    Peter J. Richardson and Masako Kurokawa

    Pages 129-148

  9. Book chapterAbstract only

    Chapter 8 - Control of Gene Expression in Basal Ganglia by Adenosine Receptors

    Alistair K. Dixon and Peter J. Richardson

    Pages 149-170

  10. Book chapterAbstract only

    Chapter 9 - Knockout Mice in the Study of Dopaminergic Diseases

    Shiro Aoyama, Hiroshi Kase, ... Emiliana Borrelli

    Pages 171-191

  11. Book chapterAbstract only

    Chapter 10 - Effects of Adenosine Receptors: Experimental Models of Cognition and Motor Behavior

    Shizuo Shiozaki, Shunji Ichikawa, ... Yoshihisa Kuwana

    Pages 193-210

  12. Book chapterAbstract only

    Chapter 11 - Actions of Adenosine Antagonists in Primate Model of Parkinson's Disease

    Tomoyuki Kanda and Peter Jenner

    Pages 211-227

  13. Book chapterAbstract only

    Chapter 12 - Selective Adenosine A2AReceptor Antagonism as an Alternative Therapy for Parkinson's Disease: A Study in Nonhuman Primates

    A Hadj Tahar, R. Grondin, ... H. Kase

    Pages 229-244

  14. Book chapterAbstract only

    Chapter 13 - Neurobiology of Adenosine Receptors: Adenosine and Its Metabolites in Movement Disorders

    Masahiro Nomoto

    Pages 245-255

  15. Book chapterAbstract only

    Chapter 14 - The Relevance of Adenosine A2A Antagonists to the Treatment of Parkinson's Disease: Concluding Remarks

    Peter Jenner

    Pages 257-263

  16. Book chapterNo access

    Index

    Pages 265-275

About the book

Description

This book is the first definitive overview on adenosine receptor antagonists and their application to the treatment of Parkinson's Disease. The effect of these novel non-dopamine drugs on vitro and in vivo systems clearly shows their potential for the treatment of this debilitating disease. This book covers how the Parkinson's disease antagonist drug, A2A, has been researched, developed, and tested. It is an essential book for researchers interested in the basal ganglia, purine biology, and Parkinson's Disease.

This book is the first definitive overview on adenosine receptor antagonists and their application to the treatment of Parkinson's Disease. The effect of these novel non-dopamine drugs on vitro and in vivo systems clearly shows their potential for the treatment of this debilitating disease. This book covers how the Parkinson's disease antagonist drug, A2A, has been researched, developed, and tested. It is an essential book for researchers interested in the basal ganglia, purine biology, and Parkinson's Disease.

Key Features

  • Discusses the discovery and development of a novel non-dopaminomimetic agent for Parkinson's disease
  • Provides the first definitive overview of adenosine antagonists and their role in the treatment of Parkinson's disease
  • Presents a new mechanism of action of adenosine A2A receptor antagonists in motor function
    Proposes a hypothesis of adenosine A2A receptor function in the striatum
  • Comprehensive overview of adenosine, its receptor subtypes, their antagonists/agonists from biochemistry, molecular biology, medicinal chemistry, physiology, pharmacology, and neurochemistry viewpoints
  • Discusses the discovery and development of a novel non-dopaminomimetic agent for Parkinson's disease
  • Provides the first definitive overview of adenosine antagonists and their role in the treatment of Parkinson's disease
  • Presents a new mechanism of action of adenosine A2A receptor antagonists in motor function
    Proposes a hypothesis of adenosine A2A receptor function in the striatum
  • Comprehensive overview of adenosine, its receptor subtypes, their antagonists/agonists from biochemistry, molecular biology, medicinal chemistry, physiology, pharmacology, and neurochemistry viewpoints

Details

ISBN

978-0-12-400405-4

Language

English

Published

2000

Copyright

Copyright © 2000 Elsevier Inc. All rights reserved

Imprint

Academic Press

You currently don’t have access to this book, however you can purchase separate chapters directly from the table of contents or buy the full version.

Purchase the book

Editors

Hiroshi Kase

Kyowa Hakko Kogyo Co. Ltd. Pharmaceutical Research and Development Division Chiyoda-ku, Tokyo

Peter J. Richardson

Department of Pharmacology University of Cambridge Cambridge, England

Peter Jenner

Neurodegenerative Diseases Research Centre Division of Pharmacology & Therapeutics Guy's King's & St. Thomas' School of Biomedical Sciences King's College London London, UK